The majority of infantile hemangiomas (IH) can be managed conservatively, but for those
requiring active treatment, management has been revolutionized in the last decade by the …

Infantile hemangiomas (IHs) are the most common benign tumors of infancy. They typically
appear after birth and undergo a period of rapid growth, followed by a gradual period of …

Importance Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of
life (early proliferative phase) may prevent further growth and the need for treatment with …

The COVID‐19 pandemic has caused significant shifts in patient care including a steep
decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile …

Importance Oral propranolol is widely considered to be first-line therapy for complicated
infantile hemangioma, but its use in patients with PHACE (posterior fossa malformations …

Infantile hemangioma (IH) is the most common benign vascular tumor of infancy, affecting
about 5% of infants. It has a characteristic growth pattern of early rapid proliferation followed …

BACKGROUND Infantile hemangioma (IH) often causes cosmetic disfigurement. Early
intervention with propranolol for large, high-risk lesions is recommended in the American …

Pediatric oncologists are increasingly involved in the management of benign vascular
tumors and their associated life‐threatening complications. Hemangiomas are the most …

Ophthalmic timolol solution is increasingly being repurposed as a topical therapeutic for a
variety of dermatologic diseases, including pyogenic granulomas, infantile hemangiomas …

Hemangioma is a type of disease caused by active glands in the body. Hemangiomas occur
in newborns up to the age of five (BATITA). This disease is indicated when a toddler has a …